Integra Lifesciences (IART) stock plummeted 5.02% in pre-market trading on Wednesday, February 26th, 2025, amid ongoing quality and supply chain challenges faced by the company.
In its fourth-quarter 2024 earnings call, Integra Lifesciences reported revenue of $443 million, representing year-over-year growth of 11.5%, but warned of potential supply disruptions in 2025 as it executes its Compliance Master Plan to address quality management system issues. The company expects to face approximately $60-$120 million in additional shipping holds beyond the $27 million already identified for the first quarter.
A key concern highlighted in the call was the production constraints for Integra Skin, one of the company's flagship products. While Integra Skin returned to historical revenue levels in Q4 2024, scheduled maintenance shutdowns and lower safety stock levels are expected to prevent the company from fully meeting demand in Q1 2025. Integra Lifesciences is investing in capacity and resiliency projects to address this issue, but the impact is projected to continue into the second quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.